Novacyt S.A. announced the appointment of David Allmond as CEO effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he wishes to retire after 13 years with the expanded Group, will stand down as CEO. David, brings relevant leadership experience in life science companies experiencing significant development and growth, and developing businesses into new global markets. Currently he is Chief Business Officer at Amryt Pharma, where he has played a key role in developing the company into a leading global rare and orphan disease drug company. Earlier in his career David held sales and marketing roles of increasing seniority at Amgen, Celgene, and Aegerion Pharmaceuticals. David will be supported by Novacyts recently strengthened executive management team. Graham is committed to ensuring a smooth transition with David and will continue to lead the Group as CEO until David joins the Company.